News & Updates

Data presented at the recent European Society for Medical Oncology (ESMO) Congress 2022 reveals a new mechanism by which very small pollutant particles in the air may cause lung cancer in people who have never smoked. The newly discovered pathway paves the way for the development of new prevention strategies and therapies, say the study authors. [Ann Oncol 2022;33(Suppl 7):S808–S869]  

New drug applications approved by US FDA as of 01 - 15 November 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Use of atomoxetine and fesoterodine (Ato-Feso), administered for one night, helps manage obstructive sleep apnoea (OSA) in patients with milder upper airway collapsibility, although this treatment may not work in some individuals, a study has shown.

Antibiotics are commonly inappropriately prescribed for upper respiratory tract infections (URTIs), reports a recent Egypt study. Nevertheless, physicians show good attitudes toward appropriate antibiotic use and knowledge of antibiotic resistance.

First-line immunotherapy treatment with atezolizumab – a PD-L1 inhibitor – offers a survival advantage over single-agent chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) who are ineligible for platinum doublets in the phase III IPSOS trial.

The use of an exhalation delivery system with fluticasone (EDS-FLU) significantly reduces acute exacerbations of chronic rhinosinusitis (CRS), which may help drive down the need for antibiotics and prevent antibiotic resistance, in the ReOpen1 and 2 randomized controlled trials.